Get real time updates directly on you device, subscribe now.
The prospective coronavirus vaccine developed by the University of Oxford is safe and induces an early immune response, suggest preliminary results of Phase 1 human trial of the vaccine. According to a press release from the medical journal The Lancet, the vaccine provoked an antibody response within 28 days and a T-cell response within 14 days.
But to get a concrete decision on the vaccine, further research is needed, says the researchers concerned.
The human trial is done involving 1,077 people aged between 18 to 55 years with no history of Covid-19 and took place in five UK hospitals from late April to late May.
In a statement, University of Oxford Professor Andrew Pollard said, ‘the immune system has two ways of finding and attacking pathogens – antibody and T cell responses. This vaccine is intended to induce both, so it can attack the virus when it’s circulating in the body, as well as attacking infected cells. We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period.’
This Story You May Like To Read Also : Now Brazil Education Minister Catches Coronavirus
The statement further said, ‘however, we need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 infection, and for how long any protection lasts.’
The vaccine has no serious adverse or side effects. But fatigue and headache are the most commonly reported reactions plus pain at the injection site, muscle ache, malaise, chills, feeling feverish and high temperature.
Globally now at least 23 Covid-19 potential vaccines are in clinical trials, according to the World Health Organization.
Comments are closed.